Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5515)
All Articles published online
|
Publishing Process of This Article
|
Jun 24, 2022 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Rallis KS, Makrakis D, Ziogas IA, Tsoulfas G. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. World J Clin Oncol 2022; 13(6): 448-472 [PMID: 35949435 DOI: 10.5306/wjco.v13.i6.448] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i6/448.htm |
| Number | Citing Articles |
| 1 |
Shukui Qin, Masatoshi Kudo, Tim Meyer, Yuxian Bai, Yabing Guo, Zhiqiang Meng, Taroh Satoh, Donatella Marino, Eric Assenat, Songzi Li, Yaxi Chen, Frederic Boisserie, Ramil Abdrashitov, Richard S. Finn, Arndt Vogel, Andrew X. Zhu. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma. JAMA Oncology 2023; 9(12): 1651 doi: 10.1001/jamaoncol.2023.4003
|
| 2 |
Meng-Xuan Zuo, Chao An, Yu-Zhe Cao, Jia-Yu Pan, Lu-Ping Xie, Xin-Jing Yang, Wang Li, Pei-Hong Wu. Camrelizumab, apatinib and hepatic artery infusion chemotherapy combined with microwave ablation for advanced hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 2024; 16(8): 3481-3495 doi: 10.4251/wjgo.v16.i8.3481
Abstract(126) |
Core Tip(133) |
Full Article(HTML)(656)
|
Full Article with Cover (PDF)-26219K(39)
|
Audio-611K(4)
|
Peer-Review Report-217K(17)
|
Answering Reviewers-122K(18)
|
Supplementary Material-384K(14)
|
Full Article (PDF)-25986K(40)
|
Full Article (XML)-136K(20)
|
Times Cited (0)
|
Total Visits (1657)
|
Open
|
| 3 |
Chih-Rong Shyr, Lang-Chi Liu, Hui-Shan Chien, Chi-Ping Huang. Immunotherapeutic Agents for Intratumoral Immunotherapy. Vaccines 2023; 11(11): 1717 doi: 10.3390/vaccines11111717
|
| 4 |
Georgios Tsoulfas, Ioannis Boletis, Vassilios Papalois. Translational research and innovation in modern transplant practice: Paradigms from Greece and around the world. World Journal of Transplantation 2023; 13(2): 25-27 doi: 10.5500/wjt.v13.i2.25
|
| 5 |
Man Yao, Shufang Liang, Binbin Cheng. Role of exosomes in hepatocellular carcinoma and the regulation of traditional Chinese medicine. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1110922
|
| 6 |
Anca Zgura, Mugur Cristian Grasu, Radu Lucian Dumitru, Letitia Toma, Laura Iliescu, Cosmin Baciu. An Investigative Analysis of Therapeutic Strategies in Hepatocellular Carcinoma: A Raetrospective Examination of 23 Biopsy-Confirmed Cases Emphasizing the Significance of Histopathological Insights. Cancers 2024; 16(10): 1916 doi: 10.3390/cancers16101916
|
| 7 |
Ning Zhang, Cailing Lu, Jiao Mo, Xinhang Wang, Simi Liao, Ningjing Liang, Mei Feng, Tingting Tang, Yijie Wu, Yunqing Li, Chunhua Lan, Chengying Chen, Qianqian Shi, Lancheng Wei, Zhijian Zheng, Yu Lei, Zhiming Zhang, Shen Tang, Xiyi Li. LCMT1 indicates poor prognosis and is essential for cell proliferation in hepatocellular carcinoma. Translational Oncology 2023; 27: 101572 doi: 10.1016/j.tranon.2022.101572
|
| 8 |
Xicai Li, Jingquan Huang, Qiulin Wu, Qiang Du, Yingyu Wang, Yubin Huang, Xiaoyong Cai, David A. Geller, Yihe Yan. Inhibition of Checkpoint Kinase 1 (CHK1) Upregulates Interferon Regulatory Factor 1 (IRF1) to Promote Apoptosis and Activate Anti-Tumor Immunity via MICA in Hepatocellular Carcinoma (HCC). Cancers 2023; 15(3): 850 doi: 10.3390/cancers15030850
|